<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-049995</identifier>
<setSpec>0001-6640</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Herpes zoster in a patient with Crohn´s disease being treated with azathioprine</dc:title>
<dc:description xml:lang="en">Azathioprine (AZA) and its active metabolite 6-mercaptopurine(6-MP) are the most widely used immunomodulatory drugs in Crohn's disease. They are well tolerated, although they do have potentially serious side effects. Complications in the form of infections occur several months after the start of treatment. Herpes zoster infection, although uncommon in Crohn's disease patients treated with AZA or 6-MP, can occur, the incidence being 2% to 3%. There have been no reports of herpes zoster infection in Crohn's disease p tients who were not being treated with immunomodulatory drugs. In the case of Crohn's disease patients infected with herpes zoster, the recommended treatment is administration of acyclovir and cessation of immunomodulatory therapy for 2 to 3 weeks until the true virulence of the virus is known</dc:description>
<dc:creator>Espín Jaime, B</dc:creator>
<dc:creator>Navas López, V. M</dc:creator>
<dc:creator>Delgado Pecellin, I</dc:creator>
<dc:creator>Rodríguez Herrera, A</dc:creator>
<dc:creator>Rodríguez Ruiz, J. R</dc:creator>
<dc:creator>Pizarra Martín, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La azatioprina (AZA) y su metabolito activo, la 6-mercaptopurina(6-MP), son los fármacos inmunomoduladores más utilizados en la enfermedad de Crohn (EC). Son bien tolerados, pero no están exentos de efectos secundarios potencialmente graves, como las complicaciones infecciosas que ocurren varios meses después del inicio del tratamiento. El herpes zoster es infrecuente en pacientes con EC en tratamiento con AZA o 6-MP, con una incidencia del 2-3%. No hay casos descritos de herpes zoster en pacientes con EC sin tratamiento inmunomodulador. Ante un caso de herpes zoster, la actitud podría ser iniciar tratamiento con aciclovir tan pronto como aparezcan las lesiones y suspender el tratamiento inmunomodulador durante 2-3 semanas hasta que se conozca la verdadera virulencia del virus de la varicela zoster</dc:description>
<dc:source>Acta Pediatr Esp;64(8): 402-404, sept. 2006.</dc:source>
<dc:identifier>ibc-049995</dc:identifier>
<dc:title xml:lang="es">Herpes zoster en un paciente con enfermedad de Crohn en tratamiento con azatioprina</dc:title>
<dc:subject>^d220^s22073</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d23973^s22012</dc:subject>
<dc:subject>^d1394^s22020</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d6721^s22012</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:type>article</dc:type>
<dc:date>200609</dc:date>
</metadata>
</record>
</ibecs-document>
